COLL Q3 2018 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$70M+487.2% YoY

Gross Profit

$24M34.4% margin

Operating Income

-$11M-15.9% margin

Net Income

-$17M-23.5% margin

EPS (Diluted)

$-0.50

QoQ Revenue Growth

-3.9%

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

$39M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$647M

Total Liabilities

$576M

Stockholders' Equity

$71M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$70M	$12M	+487.2%
Gross Profit	$24M	$11M	+112.1%
Operating Income	-$11M	-$13M	+16.7%
Net Income	-$17M	-$13M	-24.4%

Revenue Segments

Nucynta

$53M76%

Xtampza

$17M24%